In vitro Anti-proliferative Characteristics of Flavonoids and Diazepam on MDA-MB-231 Breast Cancer Cells

Flavonoid류와 diazepam의 시험관 내 MDA-MB-231 유방암세포 증식 억제 효과

  • Kim, Ji-Kwan (Department of Pharmacology, School of Medicine, Kyungpook National University) ;
  • Lee, Maan-Gee (Department of Pharmacology and 1Nuclear Medicine, School of Medicine, Kyungpook National University) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, School of Medicine, Kyungpook National University) ;
  • Ha, Jeoung-Hee (Department of Pharmacology, School of Medicine, Kyungpook National University)
  • 김지관 (경북대학교 의학전문대학원 약리학교실) ;
  • 이만기 (경북대학교 의학전문대학원 약리학교실) ;
  • 이재태 (경북대학교 의학전문대학원 핵의학교실) ;
  • 하정희 (경북대학교 의학전문대학원 약리학교실)
  • Published : 2009.08.30


The beneficial use of sedatives is often required for medically ill patients. This study examined the effect of plant flavonoids and diazepam peripheral-type benzodiazepine receptor (PBR) activation and glucose utilization in breast cancer cells, along with their interactions. In estrogen receptor negative MDA-MB-231 cells, the anti-proliferative activity of fisetin (3,7,3',4'-tetrahydroxyflavone) and diazepam was more prominent than in estrogen receptor positive MCF-7 cells. Unlike PBR ligands, treatment with $10^{-6}$ M concentration of diazepam for 3 days exhibited anti-proliferative effects, while similar to apigenin (4',5,7-Trihydroxyflavone) and fisetin, diazepam hardly affected the PBR mRNA expression by MDA-MB-231 cells. Treatment with $10^{-6}$ M concentration of flavonoids and diazepam for 3 days inhibited the glucose utilization of MDA-MB-231 cells. Treatment with $10^{-6}$ M concentration of flavonoids and diazepam for 6 days showed increased cytotoxicity and reduced the PBR mRNA expression of the MDA-MB-231 cells. Apigenin enhanced diazepam-induced anti-proliferative effects on the MDA-MB-231 cells as well. All together, this study showed the in vitro anti-proliferative activity of flavonoids and diazepam on MDA-MB-231 breast cancer cells, plus additive enhancements. In conclusion, this study provides experimental basis for advanced trials in the future.


  1. Binder, C., L. Binder, D. Marx, A. Schauer, and W. Hiddemann. 1997. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res. 17, 4299-4304
  2. Block, K. I., C. Gyllenhaal, and M. N. Mead. 2004. Safety and efficacy of herbal sedatives in cancer care. Integr. Cancer Ther. 32, 128-148
  3. Boitano, A., J. A. Ellman, G. D. Glick, and A. W. Jr. Opipari. 2003. The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells. Cancer Res. 63, 6870-6876
  4. Brusselmans, K., R. Vrolik, G. Verhoeven, and J. V. Swinnen. 2005. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J. Biol. Chem. 280, 5636-5645
  5. Cardenas, M., M. Marder, V. C. Blank, and L. P. Roguin. 2006. Antitumor activity of some naural flavonoids and synthetic derivatives on various human and murine cancer cell lines. Biol. Med. Chem. 14, 2966-2971
  6. Corsi, L., E. Geminaniani, R. Avallone, and M. Baraldi. 2005. Nuclear location-dependent role of peripheral benzodiazepine receptor (PBR) in hepatic tumoral cell lines proliferation. Life Sci. 76, 2523-2533
  7. Decaudin, D. 2004. Peripheral benzodiazepine receptor and its clinical targeting. Anticancer Drugs 15, 737-745
  8. Fennell, D. A., M. Corbo, A. Pallaska, and F. E. Cotter. 2001. Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK11195 involves de novo generation of reactive oxygen species. Br. J. Cancer 84, 1397-1404
  9. Fernandez, S. P., C. Wasoski, L. M. Loscalzo, R. E. Granger, G. A. R. Johnston, A. C. Paladini, and M. Marder. 2006. Central nervous system depressant action of flavonoid glycosides. Eur. J. Pharm. 539, 168-176
  10. Ha, J. H., J. T. Lee, I. H. Cho, K. A. Chun, G. E. Park, H. C. Choi, K. Y. Lee, S. H. Kim, K. Suk, I. K. Kim, and M. G. Lee. 2007. Upregulation of PBR mRNA expression in human neuroblastoma cells by flavonoids. Phytomedicine 14, 232-235
  11. Hans, Z., R. S. Slack, W. Lia, and V. Papadopoulos. 2003. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J. Recept. Signal Transduct. Res. 23, 225-238
  12. Harmon, A. W. and Y. M. Pate. 2004. Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res. 85, 103-110
  13. Kale, A., S. Gawande, and S. Kotwal. 2008. Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother. Res. 22, 567-577
  14. Kim, D. H., J. T. Lee, I. K. Lee, and J. H. Ha. 2008. Comparative anticancer effects of flavonoids and diazepam in cultured cancer cells. Biol. Pharm. Bull. 31, 255-259
  15. Kuo, P. C., H. F. Liu, and J. L. Chao. 2004. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J. Biol. Chem. 279, 55875-55885
  16. Lima, S. A. C., J. Tavares, and P. Gameiro. 2008. Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype. Eur. J. Pharm. 581, 30-36
  17. Maaser, K., M. Hopfner, A. Jansen, G. Weisunger, M. Gavish, A. P. Kozikowski, A. Weizman, P. Carayon, E. O. Riecken, M. Zeitz, and H. Scherubi. 2001. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br. J. Cancer 85, 1771-1780
  18. Marder, M. and A. C. Paladini. 2002. GABA (A)-receptor ligands of flavonoid structure. Curr. Top. Med. Chem. 2, 853-867
  19. Mizoguchi, K., R. Ikeda, H. Shoji, Y. Tanaka, X.-L. Jin, Y. Kase, S. Takeda, W. Maruyama, and T. Tabira. 2009. Saiko-ka-ryudotsu-borei-to, a herbal medicine, prevents chronic stress-induced anxiety in rats: comparision with diazepam. Nat. Med. (Tokyo) 63, 69-74
  20. Ognibene, E., P. Bovicelli, W. Adriani, L. Saso, and G. Laviola. 2008. Behavioral effects of 6-bromoflavanone and 5-methoxy-6, 8-dibromoflavanone as anxiolytic compounds. Prog. Neuro-psychoph. 32, 128-134
  21. Oudard, S., L. Miccoli, B. Dutrillaux, and M. F. Poupon. 1998. Targeting the gene of glucose metabolism for the treatment of advanced gliomas. Bull. Cancer 85, 622-626|
  22. Pretner, E., H. Amri, W. Li, R. Brown, C. S. Lin, E. Makariou, F. V. Defeudis, K. Drieu, and V. Papadopoulos. 2006. Cancer-related overexpression of the peripheral-type benzodiazepine receptor and cytostatic anticancer effects of Ginkgo biloba extract (Egb 761). Anticancer Res. 26, 9-22
  23. Shaheen, A. A., M. A. Hamdy, A. A. Kheir-Eldin, Pel-Fattah, and A. A. Lindstrom. 1993. Effect of pretreatment with vitamin E or diazepam on brain metabolism of stressed rats. Biochem. Pharmacol. 46, 194-197
  24. Walter, R. B., B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum, and D. E. Banker. 2004. The peripheral bezodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 103, 4276-4284
  25. Wasoski, C., M. Marder, H. Viola, J. H. Medina, and A. C. Paladini. 2002. Isolation & identification of 6-methylapigenin, a competitive ligand for the brain GABA(A) receptors, from Valeriana Wallichii. Planta Med. 68, 934-936
  26. Younes, M., R. W. Brown, D. R. Mody, I. Fernandez, and R. Laucirica. 1995. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 15, 2895-2898
  27. Zhuang, H., R. Hustinx, and A. Alavi. 2006. Effect of diazepam on the efficacy of dual-phase FDG PET imaging. Eur. J. Nucl. Med. Mol. Imaging 33, 228-229